Department of Biosciences, Biotechnologies and Pharmacological Sciences and Center of Excellence in Comparative Genomics, University of Bari, Bari, Italy.
PLoS One. 2012;7(3):e33145. doi: 10.1371/journal.pone.0033145. Epub 2012 Mar 5.
One mechanism proposed for reducing the risk of calcium renal stones is activation of the calcium-sensing receptor (CaR) on the apical membranes of collecting duct principal cells by high luminal calcium. This would reduce the abundance of aquaporin-2 (AQP2) and in turn the rate of water reabsorption. While evidence in cells and in hypercalciuric animal models supports this hypothesis, the relevance of the interplay between the CaR and AQP2 in humans is not clear. This paper reports for the first time a detailed correlation between urinary AQP2 excretion under acute vasopressin action (DDAVP treatment) in hypercalciuric subjects and in parallel analyzes AQP2-CaR crosstalk in a mouse collecting duct cell line (MCD4) expressing endogenous and functional CaR. In normocalciurics, DDAVP administration resulted in a significant increase in AQP2 excretion paralleled by an increase in urinary osmolality indicating a physiological response to DDAVP. In contrast, in hypercalciurics, baseline AQP2 excretion was high and did not significantly increase after DDAVP. Moreover DDAVP treatment was accompanied by a less pronounced increase in urinary osmolality. These data indicate reduced urinary concentrating ability in response to vasopressin in hypercalciurics. Consistent with these results, biotinylation experiments in MCD4 cells revealed that membrane AQP2 expression in unstimulated cells exposed to CaR agonists was higher than in control cells and did not increase significantly in response to short term exposure to forskolin (FK). Interestingly, we found that CaR activation by specific agonists reduced the increase in cAMP and prevented any reduction in Rho activity in response to FK, two crucial pathways for AQP2 translocation. These data support the hypothesis that CaR-AQP2 interplay represents an internal renal defense to mitigate the effects of hypercalciuria on the risk of calcium precipitation during antidiuresis. This mechanism and possibly reduced medulla tonicity may explain the lower concentrating ability observed in hypercalciuric patients.
一种降低钙肾结石风险的机制是,通过高腔钙激活集合管主细胞的钙敏感受体 (CaR),从而减少水通道蛋白-2 (AQP2) 的丰度,并进而减少水的重吸收速率。虽然细胞和高钙尿动物模型中的证据支持这一假说,但 CaR 和 AQP2 之间相互作用在人类中的相关性尚不清楚。本文首次详细报告了在高钙尿症患者中,急性血管加压素作用下(DDAVP 治疗)的尿 AQP2 排泄与平行分析在表达内源性和功能性 CaR 的小鼠集合管细胞系(MCD4)中 AQP2-CaR 串扰之间的详细相关性。在正常钙尿症患者中,DDAVP 给药导致 AQP2 排泄显著增加,同时尿渗透压增加,表明对 DDAVP 有生理反应。相比之下,在高钙尿症患者中,基础 AQP2 排泄量较高,DDAVP 给药后并未显著增加。此外,DDAVP 治疗伴随着尿渗透压增加不明显。这些数据表明,高钙尿症患者对血管加压素的尿液浓缩能力降低。与这些结果一致,MCD4 细胞中的生物素化实验表明,暴露于 CaR 激动剂的未刺激细胞中的膜 AQP2 表达高于对照细胞,并且在短期暴露于 forskolin (FK) 时不会显著增加。有趣的是,我们发现特定激动剂激活 CaR 会减少 cAMP 的增加,并防止 FK 引起的 Rho 活性降低,这是 AQP2 易位的两个关键途径。这些数据支持 CaR-AQP2 相互作用代表内部肾脏防御机制的假说,以减轻抗利尿时高钙尿对钙沉淀风险的影响。这种机制和可能降低的髓质紧张度可能解释了在高钙尿症患者中观察到的浓缩能力降低。